Intech Investment Management LLC Sells 9,802 Shares of Kymera Therapeutics, Inc. $KYMR

Intech Investment Management LLC cut its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 29.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,990 shares of the company’s stock after selling 9,802 shares during the period. Intech Investment Management LLC’s holdings in Kymera Therapeutics were worth $1,003,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its position in shares of Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after acquiring an additional 540 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Kymera Therapeutics during the first quarter valued at $68,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Kymera Therapeutics by 15.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company’s stock valued at $110,000 after purchasing an additional 343 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its stake in shares of Kymera Therapeutics by 81.7% in the 1st quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company’s stock worth $136,000 after buying an additional 2,230 shares in the last quarter.

Kymera Therapeutics Stock Performance

KYMR opened at $65.59 on Tuesday. The stock’s 50 day moving average price is $58.68 and its 200-day moving average price is $47.75. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $68.80. The stock has a market cap of $4.72 billion, a price-to-earnings ratio of -18.27 and a beta of 2.32.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The business had revenue of $2.76 million for the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $60.99, for a total transaction of $1,829,700.00. Following the completion of the sale, the chief executive officer owned 660,482 shares in the company, valued at $40,282,797.18. This trade represents a 4.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 79,220 shares of the business’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total transaction of $3,961,000.00. Following the completion of the sale, the chief financial officer directly owned 227,409 shares of the company’s stock, valued at approximately $11,370,450. This trade represents a 25.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 206,910 shares of company stock valued at $11,402,648 in the last three months. 16.01% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KYMR. B. Riley upped their target price on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Barclays boosted their price objective on Kymera Therapeutics from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Guggenheim began coverage on Kymera Therapeutics in a report on Monday, November 3rd. They issued a “buy” rating and a $90.00 target price for the company. Finally, BTIG Research increased their price target on Kymera Therapeutics from $59.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $69.75.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.